Acute myeloid leukaemia: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• FLT3 36
• TP53 9
• NPM1 27
• IDH 29
• KMT2A 20
• RUNX1 2
• CD123 19
• BCL-2 10
• ABL1 2
• CD33 17
• PI3K 3
• mTOR 0
• KIT 3
• JAK 1
• CD19 8
• MAPK 0
• STAT3 0
• ERK 0
• AKT 0
• CD38 6
• HDAC 2
• MYC 1
• NRF2 0
• PD-1 4
• PPAR 0
• CXCR4 0
• BRD4 0
• PD-L1 0
• RAS 0
• STING 1
• HIF-1 0
• TIM-3 0
• METTL3 0
• CD47 1
• CTNNB1 0
• JNK 0
• KRAS 0
• MEK 0
• PARP 3
• EZH2 0
• IL-6 2
• BRAF 0
• EGFR 0
• FTO 0
• HSP90 0
• PDGFR 0
• PTEN 0
• CDK4/6 0
• FGFR 2
• GPX4 0
• HMGB1 0
• NLRP3 0
• NRAS 0
• SHP2 0
• AMPK 0
• CD20 1
• IL-15 1
• MDM2 0
• PINK1 0
• PKM2 0

24 of 1,932 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · F31

  Therapeutic restoration of CUX1 in -7/del(7q) acute myeloid leukemia

  University of Chicago· Chicago, United States· US$50,114 awarded in fiscal year 2026· until Sept 2029

• NIH NCI · R01

  Overcoming ovarian cancer chemoresistance by co-targeting senescence and apoptosis

  Harvard University D/B/A Harvard School of Public Health· Boston, United States· US$390,447 awarded in fiscal year 2026· until Aug 2031

• NIH NINDS · R03

  Uncovering glycoRNA landscape in glioblastoma as a novel layer of immune evasion

  University of Texas Hlth Sci Ctr Houston· Houston, United States· US$78,000 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · R56

  Cooperation partners of SETBP1 in AML development

  Henry M. Jackson Fdn for the Adv Mil/Med· Bethesda, United States· US$149,152 awarded in fiscal year 2026· until Aug 2027

• NIH NCI · R21

  Loss of TET2 Promotes Leukemogenesis by Enhancing NPY-Mediated PRC2 Disruption and CTCFL Chromatin Remodeling

  Indiana University Indianapolis· Indianapolis, United States· US$407,543 awarded in fiscal year 2026· until Aug 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeting EP300/CBP in AML: from mechanistic discovery to therapeutic innovation (EPIC-AML)

  Universita Degli Studi di Parma· Parma, Italy· EU contribution €193,643· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-ERC

  Decoding the immuno-regulatory functions of the human bone marrow niche upon cancer cellular therapy (ImmunhOss)

  Lunds Universitet· Lund, Sweden· EU contribution €2,000,000· until Jan 2032

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Targeting bioactive lipids to overcome leukemia immune evasion and improve allogeneic hematopoietic stem cell transplantation outcomes (LIFE)

  Universitat Basel· Basel, Switzerland· EU contribution €1,499,511· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-ERC

  Integrating DNA Methylation and Drug Abundance at Single-Cell Resolution to Predict Cancer Drug Sensitivity (EPI-SENSOR)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Germany· EU contribution €1,499,423· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-ERC

  Perturbation-based Phosphoproteomics to Study Drug Response Heterogeneity (PerturbPhos)

  Universitatsklinikum Jena· Jena, Germany· EU contribution €1,491,735· until Sept 2031

  The disease is named only in the funder's project summary, not in the title.

10 of 499 running projects, newest first. Listed amounts together: US$329.0m + €53.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Hu8F4 in Treating Patients With Advanced Hematologic Malignancies

  NCT02530034· M.D. Anderson Cancer Center· Updated 4 Nov 2026

  “FDA Clinical Hold”Registry text, quoted unchanged. Source

• Withdrawn

  Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation

  NCT07130695· Virginia Commonwealth University· Updated 29 Oct 2026

  “Budgetary constraints”Registry text, quoted unchanged. Source

• Terminated

  Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

  NCT03150004· Medical College of Wisconsin· Updated 21 Oct 2026

  “No longer have funding support to complete the pharmacogenetics component.”Registry text, quoted unchanged. Source

• Suspended

  Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

  NCT03969446· City of Hope Medical Center· Updated 20 Oct 2026

  “Accrual goal Met”Registry text, quoted unchanged. Source

• Suspended

  Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia

  NCT06454409· City of Hope Medical Center· Updated 20 Oct 2026

  “resources”Registry text, quoted unchanged. Source

• Suspended

  8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia

  NCT05263284· City of Hope Medical Center· Updated 20 Oct 2026

  “Safety Issues, status is being updated per PI due to safety issues. Study is now Temporarily Closed to Accrual.”Registry text, quoted unchanged. Source

• Suspended

  Pyronaridine in Acute Myeloid Leukemia (AML)

  NCT05291390· Armaceutica, Inc.· Updated 19 Oct 2026

  “Change of protocol”Registry text, quoted unchanged. Source

• Terminated

  A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies

  NCT06508489· Sanofi· Updated 19 Oct 2026

  “Early discontinuation based on strategic sponsor decision not driven by any safety concerns”Registry text, quoted unchanged. Source

• Terminated

  AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission

  NCT04062266· M.D. Anderson Cancer Center· Updated 16 Oct 2026

  “\<75% participation”Registry text, quoted unchanged. Source

• Suspended

  Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

  NCT06195891· City of Hope Medical Center· Updated 15 Oct 2026

  “Timeline Adjustment”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane

  NCT05146739· National Cancer Institute (NCI)· Source

• BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

  NCT04284787· National Cancer Institute (NCI)· Source

• Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

  NCT03953898· National Cancer Institute (NCI)· Source

• Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

  NCT04802161· National Cancer Institute (NCI)· Source

• BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

  NCT04214249· National Cancer Institute (NCI)· Source

• Allogeneic iNKT Cell Therapy (agenT-797) After SCT

  NCT07758218· University of Wisconsin, Madison· Source

• National Cancer Institute "Cancer Moonshot Biobank"

  NCT04314401· National Cancer Institute (NCI)· Source

• Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia

  NCT04190550· National Cancer Institute (NCI)· Source

• Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia

  NCT03983824· National Cancer Institute (NCI)· Source

• ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS

  NCT07617363· Washington University School of Medicine· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 39
• Mendelian Randomization Analysis 3
• CRISPR-Cas Systems 17
• Gene Expression Profiling 85
• Sequence Analysis, RNA 6
• Whole Genome Sequencing 7
• Exome Sequencing 1
• Proteomics 28
• Metabolomics 10
• Mass Spectrometry 3
• Flow Cytometry 88
• Immunohistochemistry 14
• Liquid Biopsy 1
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 160
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 11
• Machine Learning 33
• Deep Learning 12
• Cohort Studies 30
• Genome-Wide Association Study 3

• Myeloid sarcoma of the septum pellucidum causing hallucinations and personality changes in an elderly woman: a case report.

  Ann Hematol, Jun 2026

• Rapid Transformation of Myelodysplastic Neoplasm to Myelodysplasia-related Acute Myeloid Leukemia with Central Nervous System Leukemia in a Young Adult.

  Ann Afr Med, Jun 2026

• Altered glymphatic-related MRI markers in children with acute lymphoblastic and myeloid leukemia at diagnosis.

  Cancer Imaging, May 2026

• Dose-dependent impairment of brain functional and microstructural connectivity during leukaemia chemotherapy.

  Br J Haematol, Mar 2026

• Predicting Plaque Vulnerability Using Machine Learning-Enabled Nanoagents Sensitized Molecular High-Resolution Magnetic Resonance Imaging Data.

  ACS Nano, Feb 2026

• Glymphatic system dysfunction and cognitive impairment in post-chemotherapy AML: A novel DTI-ALPS index study.

  Brain Res Bull, Feb 2026

• Myeloid sarcoma of the skull base: a brief review of the literature and a rare case confused radiologically with end plaque meningioma.

  Neurol Sci, Dec 2025

• Neuroleukemiosis as a manifestation of relapse of acute myeloid leukemia in a child: imaging characteristics.

  Pediatr Radiol, Dec 2025

• Central nervous system cryptococcosis with brain stem hemorrhage during chemotherapy for pediatric acute myeloblastic leukemia patient.

  J Infect Chemother, Nov 2025

• A case report: pediatric rhabdomyosarcoma presenting with bone marrow metastasis.

  BMC Pediatr, Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.